Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (141-150 of 214) with videos related to

Pageof 22
Sort By:
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
American Journal of Clinical Pathology|October 12, 2002
Differences in CD33 intensity between various myeloid neoplasmsIman Jilani, Elihu Estey, Yang Huh, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Blood|January 25, 2002
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patientsFrancesco Onida, Hagop M Kantarjian, Terry L Smith, et al.
Blood|August 2, 2003
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemiaIman Jilani, Susan O'Brien, Taghi Manshuri, et al.
Cancer Research|April 23, 2009
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cellsStefan Faderl, Ashutosh Pal, William Bornmann, et al.
Cancer|May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersJorge Cortes, Francis Giles, Susan O'Brien, et al.
Blood|November 26, 2002
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceTaghi Manshouri, Kim-anh Do, Xuemei Wang, et al.
Cancer Biomarkers : Section a of Disease Markers|February 27, 2009
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implicationsWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.
Pageof 22

Showing results (141-150 of 214) with videos related to

Sort By:
Pageof 22
Cancer|March 11, 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromesApostolia Tsimberidou, Elihu Estey, Jorge Cortes, et al.
American Journal of Clinical Pathology|October 12, 2002
Differences in CD33 intensity between various myeloid neoplasmsIman Jilani, Elihu Estey, Yang Huh, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Blood|January 25, 2002
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patientsFrancesco Onida, Hagop M Kantarjian, Terry L Smith, et al.
Blood|August 2, 2003
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemiaIman Jilani, Susan O'Brien, Taghi Manshuri, et al.
Cancer Research|April 23, 2009
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cellsStefan Faderl, Ashutosh Pal, William Bornmann, et al.
Cancer|May 27, 2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disordersJorge Cortes, Francis Giles, Susan O'Brien, et al.
Blood|November 26, 2002
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceTaghi Manshouri, Kim-anh Do, Xuemei Wang, et al.
Cancer Biomarkers : Section a of Disease Markers|February 27, 2009
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implicationsWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.
Pageof 22